Currently out of the existing stock ratings of Andrea Tan, 41 are a BUY (69.49%), 15 are a HOLD (25.42%), 3 are a SELL (5.08%).

Andrea Tan

Work Performance Price Targets & Ratings Chart

Analyst Andrea Tan, currently employed at GOLDMAN SACHS, carries an average stock price target met ratio of 49.1% that have a potential upside of 40.9% achieved within 154 days.

Andrea Tan’s has documented 115 price targets and ratings displayed on 14 stocks. The coverage is on the Healthcare sector.

Most recent stock forecast was given on KRYS, Krystal Biotech at 02-Feb-2026.

Wall Street Analyst Andrea Tan

Analyst best performing recommendations are on FATE (FATE THERAPEUTICS).
The best stock recommendation documented was for INSM (INSMED) at 5/15/2024. The price target of $49 was fulfilled within 14 days with a profit of $24.07 (96.55%) receiving and performance score of 68.96.

Average potential price target upside

of $213.53 (71.18%) on MDGL (MADRIGAL PHARMACEUTICALS).
of $25.71 (64.15%) on INSM (INSMED).
of $8.55 (34.74%) on ARWR (ARROWHEAD PHARMACEUTICALS).

CDAK Codiak BioSciences DAWN Day One Biopharmaceuticals FATE Fate Therapeutics INSM Insmed MDGL Madrigal Pharmaceuticals RLMD Relmada Therapeutics ABCL Abcellera Biologics CNTA Centessa Pharmaceuticals PLC ADR IOVA Iovance Biotherapeutics TARS Tarsus Pharmaceuticals SGMT Sagimet Biosciences Series A Common Stock ARWR Arrowhead Pharmaceuticals KOD Kodiak Sciences KRYS Krystal Biotech

Show more stocks

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Andrea Tan (GOLDMAN SACHS)